As AI agents become embedded in everyday workflows — from healthcare diagnostics to financial services chatbots — the line between human and machine continues to blur. This panel brings together industry leaders to tackle the tough questions:

• How do we trust AI agents in high-risk environments?

• What are the new rules of ownership and accountability when autonomous systems act on data?

• Is AI replacing or enhancing the human workforce — and how do we keep the balance right?

We'll unpack how AI agents are evolving across sectors, debate whether the current LLM paradigm is enough, and explore the new guardrails needed to futureproof agentic AI — without losing control.

This presentation will explore the cutting-edge applications of generative AI within the highly regulated landscape of pharmaceuticals, highlighting the potential benefits for patient care while addressing the challenges of compliance and ethical standards. At the heart of this discussion lies Novo Nordisk's pioneering work in constructing a multi-modal clinical data platform designed for the secondary use of data. This platform is particularly crucial for the cultivation of high-quality datasets that are integral to the success of generative AI. The presentation will introduce the concept of AI agents - intelligent systems equipped with the capabilities of planning, utilizing tools, and accessing memory. Moreover, the session will highlight the crucial role AI agents play in bridging the data literacy gap among teams within the pharmaceutical sector. By facilitating a deeper understanding of data, these agents empower professionals across disciplines to collaborate more effectively and make strides towards transformative healthcare solutions. 

Attendees will gain valuable perspectives on how to responsibly harness the power of generative AI to accelerate clinical breakthroughs, ensuring that ethical considerations and regulatory requirements are met.